Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Using the Composite Immune Risk Score to Assess and Modulate the Patient's Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation, a Prospective, Multicenter, Randomized Controlled Study.

NCT06208137 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT06208137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06208137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Using the Composite Immune Risk Score to Assess and Modulate the Patient's Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation, a Prospective, Multicenter, Randomized Controlled Study.
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Not applicable
Overall status
Recruiting
Start date
February 29, 2024
Completion date
April 1, 2028
Enrollment
456 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

transplant-related disorder